Subtype
Malignant Female Reproductive System Neoplasm
CI-CAN-00003157Explore in graph →
1,463 active trials11 approved drugs128 evidence items
Loading cancer entity…
Subtype
CI-CAN-00003157Explore in graph →
Clinical trials
6,253 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (740)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05669768 | Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy | unknown | Phase 2 | 46 | Sun Yat-sen UniversityOTHER | 1 | Jan 3, 2023 | clinicaltrials |
| NCT02125513 | Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer(GOGER-01) | unknown | Phase 2 | 129 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 |
| Dec 30, 2022 |
| clinicaltrials |
| NCT05665023 | Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma | unknown | Phase 2 | 37 | Yonsei UniversityOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT05641506 | A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer | unknown | Phase 2 | 50 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT05597527 | Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer | unknown | Phase 2 | 35 | Fujian Cancer HospitalOTHER_GOV | 1 | Oct 28, 2022 | clinicaltrials |
| NCT05437692 | Zimberelimab Combined With Concurrent Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer | unknown | Phase 2 | 19 | Shanghai Zhongshan HospitalOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05557565 | A Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Cervical Cancer | unknown | Phase 2 | 150 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 28, 2022 | clinicaltrials |
| NCT04398446 | Effect of Hemp-CBD on Patients With CIPN(Coala-T-CBD) | unknown | Phase 2 | 56 | Main Line HealthOTHER | 1 | Sep 1, 2022 | clinicaltrials |
| NCT04015739 | Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse(BOLD) | unknown | Phase 2 | 74 | ARCAGY/ GINECO GROUPOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT04641728 | Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer | unknown | Phase 2 | 28 | Saitama Medical University International Medical CenterOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT05179317 | Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy With or Without Bevacizumab in Women With Recurrent, or Metastatic Cervical Cancer | unknown | Phase 2 | 60 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 29, 2022 | clinicaltrials |
| NCT05479487 | Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment | unknown | Phase 2 | 132 | Xiaohua Wu MDOTHER | 0 | Jul 29, 2022 | clinicaltrials |
| NCT02562365 | Adjuvant Chemotherapy of Three-step Regimen in Ovarian Cancer(ACTS) | unknown | Phase 2 | 130 | Xiaohua Wu MDOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT05247619 | A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer | unknown | Phase 2 | 49 | Zhejiang Cancer HospitalOTHER | 1 | Jul 15, 2022 | clinicaltrials |
| NCT05444374 | A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer | unknown | Phase 2 | 48 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Jul 5, 2022 | clinicaltrials |
| NCT03827837 | Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors | unknown | Phase 2 | 265 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 1, 2022 | clinicaltrials |
| NCT05422183 | Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer | unknown | Phase 2 | 20 | Zhongda HospitalOTHER | 1 | Jun 16, 2022 | clinicaltrials |
| NCT05385068 | A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPi(t) | unknown | Phase 2 | 35 | Peking Union Medical College HospitalOTHER | 0 | May 23, 2022 | clinicaltrials |
| NCT02033616 | Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas | unknown | Phase 2 | 99 | Aivita Biomedical, Inc.INDUSTRY | 1 | Apr 25, 2022 | clinicaltrials |
| NCT05342506 | Clinical Study on the Safety, Pharmacokinetics, and Efficacy of ScTIL (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Gynecological Malignancies | unknown | Phase 2 | 30 | Peking Union Medical College HospitalOTHER | 0 | Apr 22, 2022 | clinicaltrials |
| NCT05311566 | PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer | unknown | Phase 2 | 92 | Lei LiOTHER | 1 | Apr 13, 2022 | clinicaltrials |
| NCT05311579 | Niraparib Plus Anlotinib for Recurrent Ovarian Cancer | unknown | Phase 2 | 36 | Lei LiOTHER | 1 | Apr 13, 2022 | clinicaltrials |
| NCT05310383 | Tislelizumab and Radiotherapy for Recurrent Cervical Cancer | unknown | Phase 2 | 58 | Lei LiOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05321329 | Adjuvant CAPECITABINE in High Risk PSEUDOMYXOMA PERITONEI Patients(ACAPP) | unknown | Phase 2 | 28 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05316376 | Effect of Albumin-bound Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Patients Receiving Neoadjuvant Chemotherapy for Advanced Ovarian, Fallopian Tube or Peritoneal Cancer: A Phase 2 Single Center Clinical Trial | unknown | Phase 2 | 78 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Apr 7, 2022 | clinicaltrials |
| NCT05310331 | Donafenib for Recurrent Cervical Cancer | unknown | Phase 2 | 20 | Lei LiOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT05310344 | Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer | unknown | Phase 2 | 50 | Lei LiOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT05259540 | Effect of Compound Kushen Injection Combined With Pabolizumab in the Treatment of Cervical Adenocarcinoma | unknown | Phase 2 | 42 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Mar 24, 2022 | clinicaltrials |
| NCT05290935 | Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial | unknown | Phase 2 | 122 | Lei LiOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT03976973 | BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei | unknown | Phase 2 | 62 | Mucpharm Pty LtdINDUSTRY | 0 | Mar 15, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT05211557 | Study of Fully Human B7H3 CAR-T in Treating Recurrent Malignant Ovarian Cancer | unknown | Phase 1 / Phase 2 | 15 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT01595061 | Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva | unknown | Phase 2 | 57 | Gynecologic Oncology GroupNETWORK | 1 | Dec 29, 2021 | clinicaltrials |
| NCT05170594 | A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer | unknown | Phase 2 | 60 | The Second Affiliated Hospital of Shandong First Medical UniversityOTHER | 1 | Dec 28, 2021 | clinicaltrials |
| NCT04375956 | Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients(MITO 27) | unknown | Phase 2 | 100 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Dec 20, 2021 | clinicaltrials |
| NCT03668639 | Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin | unknown | Phase 2 / Phase 3 | 80 | Christina RuhlmannOTHER | 1 | Dec 14, 2021 | clinicaltrials |
| NCT05151549 | A Study of Carilizumab Combined With Concurrent Chemoradiotherapy | unknown | Phase 2 | 46 | Hunan Cancer HospitalOTHER | 0 | Dec 9, 2021 | clinicaltrials |
| NCT04620954 | Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin(ORION-02) | unknown | Phase 1 / Phase 2 | 31 | National Cancer Centre, SingaporeOTHER | 1 | Dec 1, 2021 | clinicaltrials |
| NCT05121363 | A Clinical Trial to Evaluate TQB2858 Injection Combined With Anlotinib Hydrochloride Capsule in the Treatment of Recurrent or Metastatic Advanced Endometrial Carcinoma | unknown | Phase 2 | 113 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Nov 30, 2021 | clinicaltrials |
| NCT05137171 | AK105 Combined With Anlotinib in Patients With Cervical Cancer | unknown | Phase 2 | 36 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Nov 30, 2021 | clinicaltrials |
| NCT02065687 | Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer | unknown | Phase 2 / Phase 3 | 469 | Gynecologic Oncology GroupNETWORK | 1 | Sep 30, 2021 | clinicaltrials |
| NCT04217798 | Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer | unknown | Phase 2 | 36 | Peking Union Medical College HospitalOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT04238988 | Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer(MITO CERV 3) | unknown | Phase 2 | 45 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 27, 2021 | clinicaltrials |
| NCT04974827 | A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer | unknown | Phase 2 | 46 | Hunan Cancer HospitalOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT04887961 | Reprab Study: PLD + Trabectedin Rechallenge(MITO36) | unknown | Phase 2 | 64 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT04983550 | Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC | unknown | Phase 2 | 126 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Jul 30, 2021 | clinicaltrials |
| NCT04973904 | Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical Cancer | unknown | Phase 2 | 35 | Peking Union Medical College HospitalOTHER | 1 | Jul 22, 2021 | clinicaltrials |
| NCT02785250 | Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer | unknown | Phase 1 / Phase 2 | 85 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Jun 18, 2021 | clinicaltrials |
| NCT04918628 | Adjuvant Chemotherapy and Anti-PD-1 Antibody in Patients With Stage IIIC2-IVB Cervical Cancer(CRTCP) | unknown | Phase 2 | 50 | Taizhou HospitalOTHER | 1 | Jun 9, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Jan 3, 2023source: clinicaltrials